Apr 18, 2024 10:53 JST

Source: Eisai

Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
As a Part of FY2024 Commendation For Science and Technology by MEXT

TOKYO, Apr 18, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that “The Research on Treatments for Alzheimer’s Disease Based on its Pathological Mechanisms” has received the Award for Science and Technology (Research Category) as a part of the FY2024 Commendation for Science and Technology by the Minister of Education, Culture, Sports, Science and Technology.

The Ministry of Education, Culture, Sports, Science and Technology (MEXT) grants this award to individuals who have made remarkable achievements regarding research, development, and knowledge enhancement in the field of science and technology, with the aim of encouraging those who engage in the field and raising the standard of Japanese science and technology. This award is presented to individuals who have completed original research and development projects with high potential to contribute to the advancement of science and technology in Japan.

Teiji Kimura, Ph.D., Senior Group Officer of Eisai, and Prof. Takeshi Iwatsubo, Graduate School of Medicine and Faculty of Medicine, the University of Tokyo, were awarded this prize in recognition of the breakthrough achieved through the creation of the anti-Aβ protofibril antibody lecanemab, that was accomplished by a combination of the efforts of academia, in particular the establishment of the theoretical basis for Aβ- targeted therapy based on functional genetics and the development of a clinical trial environment incorporating imaging and biomarkers based on large-scale clinical observational studies such as J-ADNI (Japanese Alzheimer's Disease Neuroimaging Initiative), and our corporate commitment to anti-Aβ drug discovery research.

Award Theme

The Research on Treatments for Alzheimer’s Disease Based on its Pathological Mechanisms

Awardees

Prof. Takeshi Iwatsubo (Graduate School of Medicine and Faculty of Medicine, the University of Tokyo) Teiji Kimura (Global Alzheimer's Disease Head, Global Collaboration Network Lead, Senior Group Officer, Eisai Co., Ltd.)

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

Source: Eisai
Sectors: BioTech

Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai Accelerates Progress in Oncology Research with New Data at ESMO Congress 2024
September 05 2024 15:59 JST
 
Eisai Announces Status Relating to Acquisition of Own Shares
September 02 2024 14:12 JST
 
Leqembi (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain
August 22 2024 18:54 JST
 
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in the United Arab Emirates
August 14 2024 08:59 JST
 
Eisai: Update Regarding the Regulatory Status of LEQEMBI Subcutaneous Formulation
August 06 2024 12:15 JST
 
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at AAIC 2024
July 31 2024 12:59 JST
 
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union
July 29 2024 16:59 JST
 
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration
July 25 2024 09:30 JST
 
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024
July 23 2024 19:23 JST
 
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel
July 12 2024 11:56 JST
 
More Press release >>

Latest Press Release


More Latest Release >>